High‐Performance Nucleic Acid Sensors for Liquid Biopsy Applications

Das, Jagotamoy; Kelley, Shana O.

doi:10.1002/anie.201905005

Cited by 59 publications

(30 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…What these advances have so far reported are complex assays involving the use of modified oligonucleotides [19], formation of branched structures upon DNA recognition [20], molecular switches [21], nanostructured electrode modifications [18], etc., therefore ultimately having a limited chance of manufacture and clinical uptake. The current state-of-the-art in terms of general nucleic acid liquid biopsies [22] and electrochemical detection of ctDNA biomarkers [23] have been well-reviewed recently.…”

Section: Introductionmentioning

confidence: 99%

Developing a Low-Cost, Simple-to-Use Electrochemical Sensor for the Detection of Circulating Tumour DNA in Human Fluids

et al. 2020

View full text Add to dashboard Cite

It is well-known that two major issues, preventing improved outcomes from cancer are late diagnosis and the evolution of drug resistance during chemotherapy, therefore technologies that address these issues can have a transformative effect on healthcare workflows. In this work we present a simple, low-cost DNA biosensor that was developed specifically to detect mutations in a key oncogene (KRAS). The sensor employed was a screen-printed array of carbon electrodes, used to perform parallel measurements of DNA hybridisation. A DNA amplification reaction was developed with primers for mutant and wild type KRAS sequences which amplified target sequences from representative clinical samples to detectable levels in as few as twenty cycles. High levels of sensitivity were demonstrated alongside a clear exemplar of assay specificity by showing the mutant KRAS sequence was detectable against a significant background of wild type DNA following amplification and hybridisation on the sensor surface. The time to result was found to be 3.5 h with considerable potential for optimisation through assay integration. This quick and versatile biosensor has the potential to be deployed in a low-cost, point-of-care test where patients can be screened either for early diagnosis purposes or monitoring of response to therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Developing a Low-Cost, Simple-to-Use Electrochemical Sensor for the Detection of Circulating Tumour DNA in Human Fluids

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Among the main categories of cNAs, circulating tumor DNA (ctDNA) and microRNAs (miRNAs) have been receiving increased attention for use in biosensor-based detection strategies. The number of plasmonic applications dedicated to the monitoring of cNAs in blood samples is growing rapidly, although the size of ctDNA fragments and miRNA molecules has limited clinical analysis primarily to LSPR and SERS detection schemes [57].…”

Section: Nucleic Acidsmentioning

confidence: 99%

“…The dysregulation of miRNA is associated with the proliferation and metastasis in cancer progression, along with the pathogenesis of diabetes, neurodevelopmental disorders, cardiovascular disease or hematological disorders. Since miRNA expression in peripheral circulation can be connected with disease outcomes, the monitoring of miRNAs in bodily fluids represents a promising approach in clinical diagnosis and drug therapy [5,57,58]. While miRNAs have already been exploited as circulating biomarkers by conventional sequencing methods such as PCR, recent plasmonic configurations may also be compatible with the analysis of low concentrations of miRNAs in complex matrices.…”

Section: Micrornamentioning

confidence: 99%

“…Monitoring of ctDNA in the peripheral blood may be a very useful way to obtain information about potential gene mutations. Because ctDNA fragments with more than 150 base pairs could limit plasmonic detection in nanoparticle-based approaches [57], only a recent strategy takes advantage of an LSPR gold-nanorod-based platform for the sequence-specific detection of ctDNA point mutations in spiked healthy patient serum. To investigate specific point mutations, peptide nucleic acid (PNA) probes were conjugated to gold nanorods, and the LSPR absorbance was measured after exposure to synthetic ctDNA at various concentrations [62].…”

Section: Micrornamentioning

confidence: 99%

See 1 more Smart Citation

Low-Fouling Substrates for Plasmonic Sensing of Circulating Biomarkers in Biological Fluids

Mauriz

2020

Biosensors

View full text Add to dashboard Cite

The monitoring of biomarkers in body fluids provides valuable prognostic information regarding disease onset and progression. Most biosensing approaches use noninvasive screening tools and are conducted in order to improve early clinical diagnosis. However, biofouling of the sensing surface may disturb the quantification of circulating biomarkers in complex biological fluids. Thus, there is a great need for antifouling interfaces to be designed in order to reduce nonspecific adsorption and prevent inactivation of biological receptors and loss of sensitivity. To address these limitations and enable their application in clinical practice, a variety of plasmonic platforms have been recently developed for biomarker analysis in easily accessible biological fluids. This review presents an overview of the latest advances in the design of antifouling strategies for the detection of clinically relevant biomarkers on the basis of the characteristics of biological samples. The impact of nanoplasmonic biosensors as point-of-care devices has been examined for a wide range of biomarkers associated with cancer, inflammatory, infectious and neurodegenerative diseases. Clinical applications in readily obtainable biofluids such as blood, saliva, urine, tears and cerebrospinal and synovial fluids, covering almost the whole range of plasmonic applications, from surface plasmon resonance (SPR) to surface-enhanced Raman scattering (SERS), are also discussed.

show abstract

“…Previous literature reports include micro/nanomaterial-based systems for multiomics technologies and precision oncology [ 1 ], an overview of the existing liquid biopsy technologies in general [ 2 ], nanoarchitecture frameworks for electrochemical miRNA detection [ 4 ], nanotechnology-based liquid biopsy applications for ctDNA and exosomes detection [ 10 ], nucleic acids sensors for liquid biopsy applications [ 25 ] and plasmonic and supermagnetic nanomaterials for liquid biopsy applications [ 24 , 35 ]. The present review reports on all the nanomaterials used in emerging liquid biopsy applications, targeting all the relevant biomarkers; furthermore, the analytical performance of the nanomaterials is also evaluated.…”

Section: Introductionmentioning

confidence: 99%

Nanotechnology in emerging liquid biopsy applications

Kalogianni

2021

Nano Convergence

View full text Add to dashboard Cite

Liquid biopsy is considered as the most attractive alternative to traditional tissue biopsies. The major advantages of this approach lie in the non-invasive procedure, the rapidness of sample collection and the potential for early cancer diagnosis and real-time monitoring of the disease and the treatment response. Nanotechnology has dynamically emerged in a wide range of applications in the field of liquid biopsy. The benefits of using nanomaterials for biosensing include high sensitivity and detectability, simplicity in many cases, rapid analysis, the low cost of the analysis and the potential for portability and personalized medicine. The present paper reports on the nanomaterial-based methods and biosensors that have been developed for liquid biopsy applications. Most of the nanomaterials used exhibit great analytical performance; moreover, extremely low limits of detection have been achieved for all studied targets. This review will provide scientists with a comprehensive overview of all the nanomaterials and techniques that have been developed for liquid biopsy applications. A comparison of the developed methods in terms of detectability, dynamic range, time-length of the analysis and multiplicity, is also provided.

show abstract

High‐Performance Nucleic Acid Sensors for Liquid Biopsy Applications

Cited by 59 publications

References 127 publications

Developing a Low-Cost, Simple-to-Use Electrochemical Sensor for the Detection of Circulating Tumour DNA in Human Fluids

Developing a Low-Cost, Simple-to-Use Electrochemical Sensor for the Detection of Circulating Tumour DNA in Human Fluids

Low-Fouling Substrates for Plasmonic Sensing of Circulating Biomarkers in Biological Fluids

Nanotechnology in emerging liquid biopsy applications

Contact Info

Product

Resources

About